1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

  • February 2016
  • 42 pages
  • La Merie Publishing
Report ID: 3686480

Summary

Table of Contents

Search Inside

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

This Competitive Intelligence Report provides a competitor evaluation in the field of approved and investigational vaccines and therapeutics against one or more serotypes of Dengue Virus for prophylaxis or treatment of Dengue fever as of February 2016. The report covers live attenuated or whole virus vaccines, recombinant subunit and DNA-based vaccines for prophylaxis of Dengue fever as well as therapeutic antibodies and other antivirals directed against Dengue Virus. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Dengue virus (DENV) is a mosquito-borne flavivirus that infects at least 390 million people per year. It is estimated that nearly half the world's population is at risk for dengue infection. The primary mosquito vector for dengue, Aedes aegypti, continues to spread widely and into new habitats due to increased urbanization and climate change.

Dengue vaccines could have beneficial individual-level effects by reducing the probability of infection given exposure to an infected mosquito. In addition, with increasing vaccine coverage in a population, vaccines could reduce the overall transmission in the entire community, even to unvaccinated people, and thus have indirect or herd effects. The first Dengue vaccine only recently has been approved in three countries and several more vaccine candidates are in the pipeline.

Therapeutic antibodies and other antiviral agents might help in the post-exposure prophylaxis and treatment of Dengue virus-infected indivivuals. Several candidates are in the development pipeline. Preclinical studies of a candidate antibody have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its continued development as a single administration for the treatment of dengue virus infection.

The report includes a compilation of currently active projects in research and development of vaccines targeting Dengue virus for prophylaxis of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines, Antibodies and Antivirals. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Vaccine Markets in the World to 2021 - Market Size, Development, and Forecasts

  • $ 23395
  • Industry report
  • July 2017
  • by Global Research & Data Services

The expansion of the global vaccine industry is forecast to reach 1.5% p.a. in the coming years. Between 2008 and 2014 the market increased with an average annual growth of 8.6%. Currently, human vaccines ...

Vaccine Markets in Europe to 2021 - Market Size, Development, and Forecasts

  • $ 12090
  • Industry report
  • July 2017
  • by Global Research & Data Services

The industry report package Vaccine Markets in Europe to 2021 - Market Size, Development, and Forecasts offers the most up-to-date market data on the actual market situation, and future outlook for vaccines ...

Vaccine Markets in Asia to 2021 - Market Size, Development, and Forecasts

  • $ 9031
  • Industry report
  • July 2017
  • by Global Research & Data Services

The industry report package Vaccine Markets in Asia to 2021 - Market Size, Development, and Forecasts offers the most up-to-date market data on the actual market situation, and future outlook for vaccines ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.